A HOLISTIC EVALUATION OF ADVERSE EFFECTS ASSOCIATED WITH ANDROGEN DEPRIVATION THERAPY (ADT) IN PROSTATE CANCER: AN ARTIFICIAL INTELLIGENCE ASSISTED TARGETED LITERATURE REVIEW
Author(s)
Maysa Abou-Chuker, BSc1, Neerav Monga, MSc, HBSc1, Lucy Andersen, PhD, MBE, RN2, Peter Francis, MD, MBA, BS2;
1Johnson & Johnson Innovative Medicine, Toronto, ON, Canada, 2Johnson & Johnson Innovative Medicine, Raritan, NJ, USA
1Johnson & Johnson Innovative Medicine, Toronto, ON, Canada, 2Johnson & Johnson Innovative Medicine, Raritan, NJ, USA
OBJECTIVES: Androgen Deprivation Therapy (ADT) is the mainstay systemic treatment in prostate cancer (PC). ADT has a known adverse effects (AEs) profile impacting multiple organ systems. The objective of this targeted literature review (TLR) is to evaluate AEs associated with ADT in patients with PC using Evidence Co-Pilot to optimize screening.
METHODS: A targeted search was conducted in October 2025 using a Johnson and Johnson Generative Artificial Intelligence (AI) tool (Evidence CoPilot) to screen PubMed, Semantic Scholar and Clinicaltrials.gov. Studies comparing ADT use in PC patients versus non-ADT PC patients or healthy controls were targeted. The AI tool screened the 100 most relevant articles from each database. Articles were then manually reviewed (title / abstract and full text screening). Results were extracted manually, grouped by organ system, and associations were summarised.
RESULTS: Among 11,459 initial articles that were screened, 26 met inclusion criteria. Study outcomes included cardiovascular AEs (n=11), followed by metabolic AEs (n=6), cognitive AEs (n=6), with the remaining studies reporting on other AE types (e.g., musculoskeletal). Cardiovascular AEs significantly increased with ADT use, including increased risk of myocardial infarction (ranges from 19%-201%), stroke (16%-51%), cardiovascular disease (19%-38%), and cardiovascular mortality (17%-30%). ADT users had a significant increase in the risk of diabetes (25%-49%), depression (37%-41%), and decreased bone mineral density with a mean difference of -3.60 (lumbar), -3.11 (femoral neck), and -1.59 (hip) versus non-ADT users and healthy controls.
CONCLUSIONS: This TLR leveraged AI to efficiently screen relevant literature to describe the association of ADT use with AEs. ADT is often the backbone of treatment across PC, however, there remains a significant unmet need for effective castration-sparing treatments that maintain patient quality of life and minimize the risk of life-changing AEs.
METHODS: A targeted search was conducted in October 2025 using a Johnson and Johnson Generative Artificial Intelligence (AI) tool (Evidence CoPilot) to screen PubMed, Semantic Scholar and Clinicaltrials.gov. Studies comparing ADT use in PC patients versus non-ADT PC patients or healthy controls were targeted. The AI tool screened the 100 most relevant articles from each database. Articles were then manually reviewed (title / abstract and full text screening). Results were extracted manually, grouped by organ system, and associations were summarised.
RESULTS: Among 11,459 initial articles that were screened, 26 met inclusion criteria. Study outcomes included cardiovascular AEs (n=11), followed by metabolic AEs (n=6), cognitive AEs (n=6), with the remaining studies reporting on other AE types (e.g., musculoskeletal). Cardiovascular AEs significantly increased with ADT use, including increased risk of myocardial infarction (ranges from 19%-201%), stroke (16%-51%), cardiovascular disease (19%-38%), and cardiovascular mortality (17%-30%). ADT users had a significant increase in the risk of diabetes (25%-49%), depression (37%-41%), and decreased bone mineral density with a mean difference of -3.60 (lumbar), -3.11 (femoral neck), and -1.59 (hip) versus non-ADT users and healthy controls.
CONCLUSIONS: This TLR leveraged AI to efficiently screen relevant literature to describe the association of ADT use with AEs. ADT is often the backbone of treatment across PC, however, there remains a significant unmet need for effective castration-sparing treatments that maintain patient quality of life and minimize the risk of life-changing AEs.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO183
Topic
Clinical Outcomes
Disease
SDC: Oncology